Elsevier

The Journal of Pediatrics

Volume 165, Issue 3, September 2014, Pages 440-446
The Journal of Pediatrics

Medical Progress
Current Management of Neonatal Abstinence Syndrome Secondary to Intrauterine Opioid Exposure

https://doi.org/10.1016/j.jpeds.2014.05.010Get rights and content

Section snippets

Epidemiology of NAS

In a recent national survey, 18.3% of pregnant teens, 9% of pregnant women ages 18-25 years, and 5.9% of all pregnant women reported some illicit drug use.3 Opioids specifically are ubiquitous and the upsurge in use is contemporaneous with pain management standards set by the Joint Commission on Accreditation of Healthcare Organizations in 2001. Correspondingly, there has been a 5-fold increase in opioid use during pregnancy during the last decade, with a prevalence of 5.6 per 1000 hospital

Clinical Presentation of NAS

NAS manifestations are modulated by a combination of maternal and neonatal factors, including the opioid dose, frequency and timing before delivery, maternal pharmacokinetics (PK), placental metabolism, concurrent medications, and neonatal PK and pharmacogenomics. The clinical presentation of NAS reflects a greater abundance of opioid receptors in the nervous system and the gastrointestinal tract. These may exhibit as neurologic excitability (eg, tremors, irritability, increased muscle tone,

Assessment Tools for NAS

The Neonatal Intensive Care Unit Network Neurobehavioral Scale was developed for use in the neonatal intensive care unit to better understand the long-term implications of intrauterine exposure to opioids.17 Although the complexity of this comprehensive and sensitive research tool makes its routine use for clinical purposes impractical, it shows that opioid-exposed infants demonstrate high levels of dysregulated behavior and stress, it is predictive of worse neurodevelopmental outcome, and it

Management of Infants at Risk for NAS

The risk of withdrawal is variable and is related to the type of opioid, dose, and timing of exposure. The AAP recommends that infants exposed to shorter half-life drugs and who manifest no signs of withdrawal could be safely discharged after 3 days of observation, whereas it is reasonable to monitor infants exposed to drugs with a longer half-life, such as methadone, for a longer period of time (4-7 days).25 The authors' institutional policy calls for universal maternal drug screening during

Nonpharmacologic Treatment of NAS

Mothers participating in opioid-treatment programs should be encouraged to breastfeed their infants; active or recent illicit drug use is considered a contraindication to breastfeeding.26, 27 Breastfeeding has been associated with less severe symptoms of NAS and a reduced requirement for pharmacologic intervention.28, 29 In a recent study by Welle-Strand et al,30 this effect was found to be particularly prominent in a cohort of mother-infant dyads in which the mothers received methadone

Pharmacologic Treatment of NAS

Several medications, including paregoric, tincture of opium, phenobarbital, morphine, methadone, buprenorphine, and clonidine have been used to treat NAS. The AAP and Cochrane Reviews have concluded that opioids are ideal treatment for neonates exposed to opioids in utero.25, 35, 36 The treatment of choice is less clear for NAS secondary to exposure to substances other than opioids because of paucity of data as it relates to medications used to treat NAS and their PK, pharmacodynamics (PD), and

Adjunctive Pharmacologic Therapies

Despite best efforts to maintain monotherapy regimens, adjunctive pharmacologic agents often are required for infants who do not respond to first-line medications. Common indications for adjunctive therapy include poorly controlled signs of withdrawal despite optimizing the dose of a first-line treatment agent, a persistent inability to wean first-line treatment doses, or relapse of signs of NAS after withdrawal has been treated adequately.

Future Directions

Treatment of the maternal-infant dyad should be the goal. However, most facilities are not equipped to support the mother during the entire period of observation, and infants often are admitted to an intensive care unit after pharmacologic treatment is initiated. Regardless of the hospital set-up, few programs have the capability to adopt a more comprehensive model of care that includes sex-specific approaches to medical and mental health care; individual and group addiction treatment; advanced

First page preview

First page preview
Click to open first page preview

References (60)

  • M.J. Hayes et al.

    Epidemic of prescription opiate abuse and neonatal abstinence

    JAMA

    (2012)
  • L.J. Paulozzi et al.

    Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type

    Pharmacoepidemiol Drug Saf

    (2008)
  • S.W. Patrick et al.

    Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009

    JAMA

    (2012)
  • R. Massatti et al.

    Neonatal abstinence syndrome and drug use among pregnant women in Ohio: 2004-2011

    (2013)
  • H.E. Jones et al.

    Neonatal abstinence syndrome after methadone or buprenorphine exposure

    N Engl J Med

    (2010)
  • K.J. Anand et al.

    Tolerance and withdrawal from prolonged opioid use in critically ill children

    Pediatrics

    (2010)
  • I. Chasnoff et al.

    Validation of the 4P's Plus© screen for substance use in pregnancy validation of the 4P's Plus

    J Perinatol

    (2007)
  • J. Keegan et al.

    Addiction in pregnancy

    J Addict Dis

    (2010)
  • E.M. Wachman et al.

    Association of OPRM1 and COMT Single-Nucleotide Polymorphisms With Hospital Length of Stay and Treatment of Neonatal Abstinence Syndrome

    JAMA

    (2013)
  • D. Chan et al.

    New methods for neonatal drug screening

    NeoReviews

    (2003)
  • D. Montgomery et al.

    Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium

    J Perinatol

    (2006)
  • M. Coyle et al.

    Neurobehavioral effects of treatment for opiate withdrawal

    Arch Dis Child-Fetal

    (2005)
  • M.L. Velez et al.

    Prenatal methadone exposure and neonatal neurobehavioral functioning

    Pediatr Res

    (2009)
  • J. Liu et al.

    Neonatal neurobehavior predicts medical and behavioral outcome

    Pediatrics

    (2010)
  • B.M. Lester et al.

    Children of addicted women

    J Addict Dis

    (2010)
  • L.P. Finnegan et al.

    Neonatal abstinence syndrome: assessment and management

    Addict Dis

    (1975)
  • P.J. Lipsitz

    A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy

    Clin Pediatr

    (1975)
  • M. Green et al.

    The Neonatal Narcotic Withdrawal Index: a device for the improvement of care in the abstinence syndrome

    Am J Drug Alcohol Abuse

    (1981)
  • W. Zahorodny et al.

    The neonatal withdrawal inventory: a simplified score of newborn withdrawal

    J Dev Behav Pediatr

    (1998)
  • M.L. Hudak et al.

    Neonatal drug withdrawal

    Pediatrics

    (2012)
  • Cited by (0)

    J.W. was supported by the National Institutes of Health (5T32HD069054). The authors declare no conflicts of interest.

    View full text